Hereditary Hemorrhagic Telangiectasia (HHT) Center
Closed Posted
- Opportunity number
- HRSA-26-092
- Agency
-
Health Resources and Services Administration
Department of Health and Human Services
- Applications due
- Award size
- Up to $2,900,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Unrestricted
- State Governments
- Points of contact
-
- Nordia Williams nwilliams1@hrsa.gov (240) 475-3310
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Health Resources and Services Administration is soliciting applications for one cooperative agreement to establish a national Hereditary Hemorrhagic Telangiectasia (HHT) Center by July 10, 2026. Eligible applicants include state governments and unrestricted domestic organizations located in the 50 states, District of Columbia, and U.S. territories, including Puerto Rico, Northern Mariana Islands, American Samoa, Guam, U.S. Virgin Islands, Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau; 501(c)(3) nonprofit organizations may apply, but individuals are not eligible.
The award totals $2,900,000 over three budget periods from September 1, 2026, through August 31, 2029. The recipient must establish a network of at least 15 clinical centers specializing in HHT treatment, develop a de-identified patient data registry compliant with HIPAA and NIST cybersecurity standards, pilot an EHR alert system to identify potential HHT patients, conduct quality improvement projects focused on expanding access and improving quality of life, provide provider education, and engage persons with lived experience in all program aspects. The recipient must establish data use agreements with clinical partners and create an advisory committee including clinicians and HHT patients.
Applications are limited to 50 pages, including agreements with other entities and budget narratives. Merit review evaluates applications on need (10 points), response and approach (40 points), performance reporting and evaluation (15 points), impact (10 points), resources and capabilities (15 points), and support requested (10 points). Recipients must comply with 2 CFR Part 200, maintain performance data, submit annual progress reports, and participate in required outcome reporting. Templates of Memoranda of Understanding and Letters of Support may be submitted at application, with signed versions acceptable post-award if they describe working relationships and deliverables.
The program is funded under CFDA 93.110 (Special Projects of Regional and National Significance).
Synopsis
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Files
| File | Type | Posted |
|---|---|---|
| HRSA-26-092 TA Presentation.pdf | ||
| HRSA 26-092 HHT Center Program FAQ.pdf | ||
| HRSA 26-092 HHT Center Program FAQ.pdf | ||
| HRSA-26-092 FINAL.pdf | ||
| HRSA-26-092 Final.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity